Veno-occlusive disease (VOD) is an inflammatory condition caused by the high-dose chemotherapy used to condition patients before stem cell transplants. The therapy damages blood vessels and cells in the liver and leads to pain, build up of fluid in the body, and abnormal liver function.
Defibrotide is an investigational drug being studied as a possible treatment for VOD. Defibrotide has been used in the past to treat kidney loss after kidney transplantation, to lower blood vessel inflammation, and to treat VOD in blood stem cell transplant patients. These studies show that defibrotide cures severe VOD in about 40 percent of patients. The purpose of this study is to evaluate the safety and effectiveness of defibrotide as a possible treatment for VOD.